Photo: FatCamera/Getty Images
Australia approves lung cancer AI from the UK
Australia's Therapeutic Goods Administration has recently granted approval for an AI-powered lung cancer detection platform developed by the United Kingdom-based Optellum.
The Virtual Nodule Clinic platform incorporates a clinically validated lung cancer prediction AI tool used for nodule risk stratification and care pathway prioritisation.
The software is already cleared or authorised for clinical use in the United States, the European Union and the UK.
Medtech launches AI on patient management system
New Zealand health IT vendor Medtech Global has unveiled an AI platform integrated directly with its widely adopted practice management system to support clinical documentation and patient record review in primary care.
The new Medtech AI generates structured consultation notes, referral letters, and correspondence, while synthesising patient histories from the Medtech Evolution PMS into a dashboard showing medications, conditions, allergies, immunisations, and recent consultations.
Based on a media release, Medtech AI processes consultation data within the PMS and writes clinician-approved outputs back into the record. It reportedly can summarise complex patient histories in about 20 seconds and support consultations through web and mobile access.
OncoRes nets $19M for breast cancer imaging
Perth-based OncoRes Medical has raised A$27 million ($19 million) in a private funding round to advance clinical development and regulatory milestones for its Elora quantitative micro-elastography imaging system.
The Elora imaging system provides real-time intraoperative assessment of tumour tissue during breast-conserving surgery by generating micro-scale maps of tissue stiffness to help surgeons detect and remove residual cancer.
Alongside this announcement, OncoRes mentioned in a media release that it is preparing for the first interventional use of its imaging system through clinical trials with six hospitals across Western Australia and Victoria. More than 110 breast cancer patients will be recruited.
The company first received Breakthrough Device Designation for Elora from the United States Food and Drug Administration in 2020.
